Gut Microbiome Dysbiosis in Patients with Endometrial Cancer vs. Healthy Controls Based on 16S rRNA Gene SequencingOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether gut microbiome imbalance is associated with endometrial cancer, given that metabolic diseases like obesity, diabetes, and hypertension are known risk factors for the cancer and gut dysbiosis can drive metabolic alterations. Researchers profiled the fecal microbial communities of endometrial cancer patients and compared them with healthy controls using 16S rRNA high-throughput gene sequencing on the Illumina NovaSeq platform. The goal was to determine whether gut microbiota composition differs between the two groups and could represent an indirect factor in endometrial cancer development.
Who was studied?
The study included 33 patients with endometrial cancer (the EC group) and 32 healthy controls (the N group). Fecal samples were collected from all participants between February 2021 and July 2021. The total number of operational taxonomic units (OTUs) identified was 28,537 in the healthy control group and 18,465 in the endometrial cancer group, with 4,771 OTUs shared between the two groups.
What were the most important findings?
This was the first study to report that alpha diversity of the gut microbiota was significantly reduced in endometrial cancer patients compared with healthy controls. There was also a significant difference in overall microbial community distribution between the two groups. Specifically, the abundance of Firmicutes, Clostridia, Clostridiales, Ruminococcaceae, Faecalibacterium, and Gemmiger_formicis decreased in the endometrial cancer group relative to controls.
What are the greatest implications of this study?
The findings suggest that gut microbiome dysbiosis, marked by reduced diversity and depletion of Faecalibacterium and related Firmicutes taxa, may be linked to endometrial cancer, potentially through metabolic pathways. Faecalibacterium species, including Faecalibacterium prausnitzii, are commonly recognized as anti-inflammatory, butyrate-producing commensals, so their depletion points toward a loss of protective microbial functions in these patients. These results support further investigation of gut microbiota as a potential indirect factor in endometrial cancer risk and as a possible target for future research.